A biologics license application for TLX250-CDx has been submitted to the FDA, as supported by the phase 3 ZIRCON trial ...

The past 12 months have seen the FDA approvals of enfortumab vedotin plus pembrolizumab for patients with locally advanced or ...

Thomas W. LeBlanc, MD, MA, discusses how the COMMANDS study, which compared luspatercept to epoetin alfa in erythropoiesis-stimulating agent (ESA)–naive, transfusion-dependent patients with low-risk ...

A panelist discusses how infusion-related reactions to monoclonal antibodies in EGFR-mutated NSCLC can be effectively managed through preventive measures demonstrated in the phase 2 SKIPPirr trial.

Evan Y. Yu, MD, discusses how systemic therapy options for newly diagnosed metastatic hormone-sensitive prostate cancer include androgen deprivation therapy (ADT) combined with chemotherapy or ...

Evan Y. Yu, MD, discusses how individualized first-line systemic therapy selection for metastatic hormone-sensitive prostate cancer (mHSPC) involves considering factors such as disease burden, patient ...

Panelists discuss how mutational burden impacts the response to frontline luspatercept in lower-risk myelodysplastic syndrome ...

During an in-person Community Case Forum event in Miami, Florida, Mike Cusnir, MD, discussed the ARANOTE study outcomes ...

A panelist discusses how comprehensive molecular testing at MBC diagnosis, including genomic profiling and ESR1 mutation status, helps guide treatment decisions and identify potential therapeutic ...

A panelist discusses how molecular testing for patients with MBC who relapse during or shortly after adjuvant endocrine therapy is crucial for detecting ESR1 mutations and other resistance mechanisms ...

A phase 1 trial evaluating FSHR-targeting CAR T cells for patients with ovarian cancer has dosed the first patient in its ...

Panelists discuss how mutational burden influences the duration of response to frontline luspatercept in lower-risk myelodysplastic syndrome (LR-MDS), as observed in the COMMANDS trial (Komrokji et al ...